| Field Name | Field Description |
|---------------------|--|
| Prior Authorization | Botulinum Toxins A&B |
| Group Description | Dotumum Toxins A&D |
| Drugs | Preferred Agents for FDA approved indications: |
| | IncobotulinumtoxinA (Xeomin) |
| | AbobotulinumtoxinA (Dysport) |
| | |
| | Non-preferred Agents: |
| | OnabotulinumtoxinA (Botox) |
| | RimabotulinumtoxinB (Myobloc) |
| | DaxibotulinumtoxinA (Daxxify) |
| C 1II | Or any newly marketed agent |
| Covered Uses | Medically accepted indications are defined using the following sources: |
| | the Food and Drug Administration (FDA), Micromedex, American |
| | Hospital Formulary Service (AHFS), United States Pharmacopeia Drug |
| | Information for the Healthcare Professional (USP DI), the Drug |
| | Package Insert (PPI), or disease state specific standard of care guidelines. |
| Exclusion Criteria | N/A |
| Required Medical | |
| Information | N/A |
| Age Restrictions | According to package insert |
| Prescriber | None |
| Restrictions | Trone |
| Coverage Duration | If all of the conditions are met, the request will be approved for 12 |
| | month duration. |
| Other Criteria | **The use of these medications for cosmetic purposes is NOT a |
| | covered benefit under the Medical Assistance program** |
| | For Initial Annuavale |
| | For Initial Approval: |
| | The drug is being used for a medically accepted indication and |
| | dose as outlined in Covered Uses |
| | The member has tried and failed standard first line therapy for |
| | their disease state and/or has a documented medical reason |
| | (intolerance, hypersensitivity, contraindication, etc.) for not |
| | using first line therapy |
| | • If the diagnosis is Chronic Migraines (≥15 days per month |
| | with headache lasting 4 hours a day or longer), the member has |
| | tried and failed, or has a medical reason for not using one drug |
| | from two of the following categories for at least 4 weeks each at |
| | a minimum effective dose: |
| | o Beta blockers (e.g. propranolol, timolol, etc.) |
| | Amitriptyline or venlafaxine |
| | o Topiramate, divalproex ER or DR, or valproic acid |
| | |

| • If the diagnosis is Overactive Bladder , the member has tried and failed 2 formulary drugs (e.g. oxybutynin) |
|---|
| |
| • If the diagnosis is Hyperhidrosis , the member has tried and |
| failed a prescription strength antiperspirant (e.g. 20% aluminum |
| chloride hexahydrate) |
| If the diagnosis is Chronic Sialorrhea, |
| Documentation is provided that the member has had |
| |

sialorrhea lasting at least 3 months The member has tried and failed, or has a medical

- o The member has tried and failed, or has a medical reason for not using, an anticholinergic medication (e.g. glycopyrrolate, hyoscyamine, benztropine)
- If the request is for a non-preferred agent, the member tried and failed a preferred agent if appropriate for the requested indication

Revision/Review Date 11/2024

For Reauthorization:

- Documentation of provider attestation that demonstrates a clinical benefit
- The requested drug is for a medically accepted dose as outlined in Covered Uses

Physician/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.